NASDAQ:GLPG Galapagos (GLPG) Stock Price, News & Analysis → See this before next week's Fed meeting (From Stansberry Research) (Ad) Free GLPG Stock Alerts $28.59 -0.18 (-0.63%) (As of 12:11 PM ET) Add Compare Share Share Today's Range$28.33▼$28.7550-Day Range$28.77▼$39.6652-Week Range$28.33▼$45.21Volume92,802 shsAverage Volume128,323 shsMarket Capitalization$1.88 billionP/E RatioN/ADividend YieldN/APrice Target$34.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Galapagos alerts: Email Address Galapagos MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside20.7% Upside$34.50 Price TargetShort InterestBearish2.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.02Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.20) to $0.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.57 out of 5 starsMedical Sector855th out of 907 stocksPharmaceutical Preparations Industry400th out of 422 stocks 2.0 Analyst's Opinion Consensus RatingGalapagos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageGalapagos has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.18% of the float of Galapagos has been sold short.Short Interest Ratio / Days to CoverGalapagos has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Galapagos has recently decreased by 2.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGalapagos does not currently pay a dividend.Dividend GrowthGalapagos does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLPG. Previous Next 2.2 News and Social Media Coverage News SentimentGalapagos has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Galapagos this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added Galapagos to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galapagos insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of Galapagos is held by insiders.Percentage Held by InstitutionsOnly 32.46% of the stock of Galapagos is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Galapagos are expected to grow in the coming year, from ($0.20) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galapagos is -12.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galapagos is -12.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalapagos has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. About Galapagos Stock (NASDAQ:GLPG)Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Read More GLPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLPG Stock News HeadlinesApril 23, 2024 | americanbankingnews.comGalapagos (NASDAQ:GLPG) Given Equal Weight Rating at Morgan StanleyApril 18, 2024 | americanbankingnews.comGalapagos (NASDAQ:GLPG) Reaches New 52-Week Low at $29.45April 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)April 4, 2024 | globenewswire.comGalapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024April 1, 2024 | msn.comGalapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: AnalystApril 1, 2024 | finance.yahoo.comGalapagos Full Year 2023 Earnings: Beats ExpectationsMarch 28, 2024 | finanznachrichten.deGalapagos NV: Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' MeetingsMarch 28, 2024 | finance.yahoo.comGalapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)March 28, 2024 | globenewswire.comGalapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' MeetingsMarch 28, 2024 | finanznachrichten.deGalapagos NV: Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardMarch 28, 2024 | msn.comBofA downgrades Galapagos to Underperform over lack of catalysts in the near termMarch 26, 2024 | globenewswire.comGalapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardMarch 20, 2024 | nasdaq.comGalapagos Enters Oversold Territory (GLPG)March 16, 2024 | finance.yahoo.comGLPG Oct 2024 45.000 putMarch 16, 2024 | finance.yahoo.comGLPG Apr 2024 42.500 putMarch 7, 2024 | seekingalpha.comGalapagos: Pipeline Still Progressing Despite Financial VolatilityMarch 7, 2024 | realmoney.thestreet.comGalapagos assumed with an Equal Weight at Morgan StanleyMarch 3, 2024 | finance.yahoo.comGLPG Mar 2024 32.500 putFebruary 27, 2024 | realmoney.thestreet.comGalapagos price target lowered by EUR 4 at BarclaysFebruary 27, 2024 | markets.businessinsider.comGalapagos (GLPG) Gets a Hold from RBC CapitalFebruary 26, 2024 | finance.yahoo.comGLPG Mar 2024 37.500 putFebruary 24, 2024 | finance.yahoo.comGalapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | globenewswire.comGalapagos announces full year 2023 results and outlook for 2024February 21, 2024 | msn.comGalapagos FY 2023 Earnings PreviewFebruary 19, 2024 | finance.yahoo.comGLPG Mar 2024 40.000 callFebruary 15, 2024 | finanznachrichten.deGalapagos NV: Galapagos presents at EBMT-EHA annual meeting 2024See More Headlines Receive GLPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:GLPG CUSIPN/A CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,123Year Founded1999Price Target and Rating Average Stock Price Target$34.50 High Stock Price Target$38.00 Low Stock Price Target$31.00 Potential Upside/Downside+19.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$229.12 million Net Margins-26.25% Pretax Margin2.35% Return on Equity-2.60% Return on Assets-1.46% Debt Debt-to-Equity RatioN/A Current Ratio9.02 Quick Ratio8.84 Sales & Book Value Annual Sales$239.72 million Price / Sales7.91 Cash Flow$0.64 per share Price / Cash Flow44.65 Book Value$45.92 per share Price / Book0.63Miscellaneous Outstanding Shares65,897,000Free Float63,979,000Market Cap$1.90 billion OptionableOptionable Beta0.24 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Paulus A. Stoffels M.D. (Age 62)Ph.D., CEO, Chairman, Interim Head of R&D Comp: $1.34MMr. Thad Huston (Age 53)Executive VP, CFO & COO Ms. Sofie Van GijselHead of Investor RelationsMs. Valeria Cnossen (Age 50)Executive VP & General Counsel Marieke VermeerschHead of Corporate CommunicationMs. Annelies Missotten (Age 51)Executive VP & Chief Human Resources Officer Ms. Ellen Van Der AarHead of DevelopmentMr. Philippe Alen M.B.A.Ph.D., Pharm.D., Senior VP & Head of Business DevelopmentMr. Dirk De NaeyerHead of Development OperationsMs. Alice DietrichHead of Medical AffairsMore ExecutivesKey CompetitorsMaravai LifeSciencesNASDAQ:MRVIPTC TherapeuticsNASDAQ:PTCTNewAmsterdam PharmaNASDAQ:NAMSGeronNASDAQ:GERNKeros TherapeuticsNASDAQ:KROSView All CompetitorsInstitutional OwnershipGAMMA Investing LLCSold 386 shares on 4/5/2024Ownership: 0.001%Wellington Management Group LLPBought 18,552 shares on 3/5/2024Ownership: 0.751%Greenlight Capital Inc.Bought 6,200 shares on 2/15/2024Ownership: 0.247%Vestal Point Capital LPBought 130,000 shares on 2/14/2024Ownership: 0.197%Barometer Capital Management Inc.Bought 3,000 shares on 2/14/2024Ownership: 0.005%View All Institutional Transactions GLPG Stock Analysis - Frequently Asked Questions Should I buy or sell Galapagos stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares. View GLPG analyst ratings or view top-rated stocks. What is Galapagos' stock price target for 2024? 5 brokers have issued 12-month target prices for Galapagos' shares. Their GLPG share price targets range from $31.00 to $38.00. On average, they anticipate the company's share price to reach $34.50 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts. How have GLPG shares performed in 2024? Galapagos' stock was trading at $40.65 on January 1st, 2024. Since then, GLPG stock has decreased by 29.7% and is now trading at $28.58. View the best growth stocks for 2024 here. When is Galapagos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our GLPG earnings forecast. What ETFs hold Galapagos' stock? ETFs with the largest weight of Galapagos (NASDAQ:GLPG) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).ERShares NextGen Entrepreneurs ETF (ERSX). What is Onno van de Stolpe's approval rating as Galapagos' CEO? 6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Galapagos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL). When did Galapagos IPO? Galapagos (GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are Galapagos' major shareholders? Galapagos' stock is owned by a number of retail and institutional investors. Top institutional investors include GAMMA Investing LLC (0.00%). How do I buy shares of Galapagos? Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLPG) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThese AI trades triggered this morning (545% return)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
